Drug Search Results
More Filters [+]

Miconazole

Alternative Names: miconazole, vusion, daktarin, brentan, Miconaz, monistat, MICONAZOL, oravig, m-zole 3 combination pack, m-zole 7 dual pack, vagistat 3, vagisil brand vagistat, lagicam antifungal, lagicam
Latest Update: 2024-12-17
Latest Update Note: News Article

Product Description

Vaginal miconazole is used to treat vaginal yeast infections in adults and children 12 years of age and older. Miconazole is in a class of antifungal medications called imidazoles. It works by stopping the growth of fungi that cause infection. (Sourced from: https://medlineplus.gov/druginfo/meds/a601203.html)

Mechanisms of Action: CYP1A2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Vaginal

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Candidiasis

Known Adverse Events: Abdominal Pain | Dysgeusia | Headache | Pain Unspecified | Diarrhea

Company: Hill Dermaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Miconazole

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Candidiasis|Otomycosis

Phase 2: Candidiasis, Vulvovaginal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MZ-1015-ESP3-054

P3

Recruiting

Otomycosis

2024-09-01

MicoFlu-C

P3

Active, not recruiting

Candidiasis

2023-06-17

2021-001201-75

P2

Active, not recruiting

Candidiasis, Vulvovaginal

2022-07-13

Recent News Events